Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker PFE · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate C… NCT03460977 · Metastatic Castration Resistant Prostate Cancer (mCRPC), Sm… Mevrometostat (PF-06821497), Enzalutamide | PFE Pfizer | Phase 1 | Recruiting | 453 | Apr 20, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment NCT07933848 · Renal Impairment, Healthy Adults Prifetrastat | PFE Pfizer | Phase 1 | Not yet recruiting | 24 | May 21, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and A… NCT07933835 · Healthy Participants PF-08166744, Placebo | PFE Pfizer | Phase 1 | Not yet recruiting | 82 | Jan 18, 2028 | Registry ↗ |
| Nov 12, 2026 | The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women W… NCT07932925 · Urinary Incontinence, Stress, Overweight and/or Obesity Berobenatide, Placebo | PFE Pfizer | Phase 3 | Not yet recruiting | 900 | Oct 13, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococ… NCT07794748 · Pneumococcal Disease PG4 Multivalent Vaccine, PG4 Multivalent Vaccine | PFE Pfizer | Phase 3 | Active, not recruiting was recruiting | 4,701 | Apr 26, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema NCT07765888 · Atopic Dermatitis Tilrekimig, Placebo | PFE Pfizer | Phase 3 | Recruiting | 375 | Mar 10, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study of MET233 in Individuals With Obesity or Overweight NCT07022977 · Obesity and Overweight MET233, Placebo | PFE Pfizer | Phase 1 | Completed | 145 | May 28, 2026 | Registry ↗ |
| Nov 12, 2026 | A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate… NCT06807268 · Eczema Abrocitinib, Placebo | PFE Pfizer | Phase 3 | Active, not recruiting was recruiting | 151 | May 2, 2027 | Registry ↗ |
| Nov 12, 2026 | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus P… NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Sigvotatug Vedotin, Pembrolizumab | PFE Pfizer | Phase 3 | Recruiting | 714 | Sep 5, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in I… NCT06587035 · Dwarfism, Pituitary Somatrogon | PFE Pfizer | — | Recruiting | 50 | Sep 5, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis NCT06294925 · Colitis, Ulcerative Etrasimod | PFE Pfizer | — | Active, not recruiting | 360 | May 13, 2027 | Registry ↗ |
| Nov 12, 2026 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple… NCT06152575 · Multiple Myeloma Elranatamab, Elotuzumab | PFE Pfizer | Phase 3 | Recruiting | 492 | Aug 26, 2026 | Registry ↗ |
| Nov 12, 2026 | A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Sta… NCT06072183 · Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo Ritlecitinib, Ritlecitinib | PFE Pfizer | Phase 3 | Active, not recruiting | 1,571 | Jul 30, 2027 | Registry ↗ |
| Nov 12, 2026 | ATGAM General Investigation NCT06039020 · Aplastic Anemia Anti-human thymocyte immunoglobulin, equine | PFE Pfizer | — | Active, not recruiting | 1 | Mar 26, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne… NCT05689164 · Duchenne Muscular Dystrophy fordadistrogene movaparvovec | PFE Pfizer | Phase 3 | Terminated | 7 | Sep 24, 2025 | Registry ↗ |
| Nov 12, 2026 | Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) NCT05650476 · Metastatic Castration-Resistant Prostate Cancer Talazoparib | PFE Pfizer | — | Available | — | — | Registry ↗ |
| Nov 10, 2026 | A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants Wi… NCT07890597 · Early Breast Cancer, Estrogen Receptor Positive (ER+), Huma… Atirmociclib, giredestrant | PFE Pfizer | Phase 3 | Not yet recruiting | 3,800 | Apr 13, 2032 | Registry ↗ |
| Nov 10, 2026 | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting P… NCT07228390 · Hidradenitis Suppurativa Ritlecitinib, Placebo | PFE Pfizer | Phase 2 | Active, not recruiting | 128 | Dec 8, 2026 | Registry ↗ |
| Nov 10, 2026 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors NCT04557449 · Liposarcoma, Prostate Cancer PF-07220060, Letrozole | PFE Pfizer | Phase 2 | Recruiting | 430 | Oct 7, 2029 | Registry ↗ |
| Nov 9, 2026 | A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple… NCT07927023 · Multiple Myeloma Elranatamab, Standard of Care | PFE Pfizer | — | Not yet recruiting | 1 | Feb 1, 2027 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate H… NCT07923981 · Hemophilia A or B marstacimab | PFE Pfizer | Phase 3 | Recruiting | 95 | Jul 2, 2029 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathi… NCT07881757 · Apnea, Sleep Disorders Berobenatide, Placebo | PFE Pfizer | Phase 3 | Recruiting was not yet recruiting | 258 | Jun 1, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the… NCT07876531 · Overweight and/or Obesity, Healthy Participants Berobenatide | PFE Pfizer | Phase 1 | Recruiting was not yet recruiting | 144 | Apr 6, 2027 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo… NCT07874633 · Obesity, Overweight Berobenatide, Placebo | PFE Pfizer | Phase 3 | Recruiting was not yet recruiting | 432 | Jun 6, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults Wi… NCT07845513 · Overweight, Obesity PF-08653944 | PFE Pfizer | Phase 1 | Active, not recruiting was not yet recruiting | 11 | Feb 21, 2027 | Registry ↗ |
| Nov 6, 2026 | Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease NCT07839871 · Respiratory Syncytial Virus (RSV) RSVpreF, Placebo | PFE Pfizer | Phase 3 | Recruiting was not yet recruiting | 920 | Mar 30, 2031 | Registry ↗ |
| Nov 6, 2026 | Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Ana… NCT07821216 · Alopecia Areata ritlecitinib | PFE Pfizer | — | Active, not recruiting | 1 | Nov 20, 2026 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults Wit… NCT07794774 · Obesity Berobenatide, Placebo | PFE Pfizer | Phase 3 | Recruiting was not yet recruiting | 197 | Feb 21, 2029 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema NCT07783425 · Atopic Dermatitis Tilrekimig, Dupilumab | PFE Pfizer | Phase 3 | Recruiting | 1,375 | Sep 8, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants NCT07573462 · Pneumococcal Disease PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | PFE Pfizer | Phase 3 | Recruiting | 2,400 | Dec 30, 2028 | Registry ↗ |
| Nov 6, 2026 | A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyo… NCT07494656 · ATTR-CM (Transthyretin Amyloid Cardiomyopathy) tafamidis 61mg (based on prescription data) | PFE Pfizer | — | Active, not recruiting | 1 | Nov 30, 2026 | Registry ↗ |
| Nov 6, 2026 | Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Popul… NCT07177209 · Ulcerative Colitis Non-Interventional Study | PFE Pfizer | — | Completed was active, not recruiting | 4,000 | Oct 30, 2026 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhib… NCT07161687 · Hemophilia A or B Marstacimab | PFE Pfizer | — | Active, not recruiting | 50 | Mar 28, 2030 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Sev… NCT07029711 · Severe Alopecia Areata Ritlecitinib higher dose, Ritlecitinib lower dose | PFE Pfizer | Phase 3 | Active, not recruiting | 208 | Dec 2, 2026 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asth… NCT06977581 · Asthma PF-07275315, Placebo | PFE Pfizer | Phase 2 | Recruiting | 252 | Mar 8, 2027 | Registry ↗ |
| Nov 6, 2026 | Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib NCT06531109 · Alopecia Areata Ritlecitinib | PFE Pfizer | — | Active, not recruiting | 450 | Apr 15, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About How a New Pneumococcal Vaccine Works in Infants NCT06524414 · Pneumococcal Disease PG4, 20-valent pneumococcal conjugate vaccine (20vPnC) | PFE Pfizer | Phase 2 | Active, not recruiting | 605 | Mar 4, 2027 | Registry ↗ |
| Nov 6, 2026 | Litfulo Capsules Special Investigation NCT06279221 · Alopecia Areata LITFULO | PFE Pfizer | — | Active, not recruiting | 664 | Jan 18, 2030 | Registry ↗ |
| Nov 6, 2026 | A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults NCT06182124 · Pneumococcal Disease Multivalent Pneumococcal Vaccine - Formulation 1, Multivale… | PFE Pfizer | Phase 1/2 | Completed | 1,710 | May 12, 2026 | Registry ↗ |
| Nov 6, 2026 | An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis NCT03950232 · Ulcerative Colitis Etrasimod | PFE Pfizer | Phase 3 | Active, not recruiting | 896 | Jun 19, 2029 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight o… NCT07919678 · Obesity, Overweight Berobenatide, Placebo | PFE Pfizer | Phase 3 | Recruiting | 656 | Aug 22, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe As… NCT07869043 · Asthma tilrekimig, Placebo | PFE Pfizer | Phase 3 | Recruiting | 1,100 | Jun 7, 2029 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to H… NCT07845500 · Obesity, Overweight and/or Obesity Semaglutide, Berobenatide | PFE Pfizer | Phase 3 | Recruiting | 660 | Feb 16, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathi… NCT07823608 · Apnea, Sleep Disorders Berobenatide, Placebo | PFE Pfizer | Phase 3 | Recruiting | 258 | Apr 30, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With… NCT07794761 · Obesity Berobenatide, Placebo | PFE Pfizer | Phase 3 | Recruiting | 180 | Mar 14, 2029 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo… NCT07792954 · Obesity, Overweight Berobenatide, Placebo | PFE Pfizer | Phase 3 | Recruiting | 300 | Mar 14, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults Wit… NCT07725809 · Overweight, Obesity PF-08653945 | PFE Pfizer | Phase 1 | Active, not recruiting was recruiting | 57 | Jan 13, 2027 | Registry ↗ |
| Nov 5, 2026 | A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweig… NCT07595549 · Obesity, Overweight and/or Obesity PF-08653944, Placebo | PFE Pfizer | Phase 3 | Recruiting | 954 | May 4, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity NCT07575932 · Overweight, Obesity PF-08653945, PF-08653944 | PFE Pfizer | Phase 2 | Active, not recruiting | 940 | Aug 4, 2027 | Registry ↗ |
| Nov 5, 2026 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors NCT07519655 · Non-Small-Cell Lung, Esophageal Cancer PF-08046033 | PFE Pfizer | Phase 1 | Recruiting | 250 | Jul 14, 2028 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances